Glaucoma, ocular hypertension
Conditions
Interventions
12 Weeks administration of Xalacom to the patients who are treated with concomitant application of two or more anti-glaucoma drugs including a PG analogs and a beta blocker over four weeks
Sponsors
Department of Ophthalmology, Kitasato University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients of glaucoma or ocular hypertension treated with applying a PG analogs and a beta blocker concomitantly 1) Patients who were fully informed and gave their written informed consent to this study 2) IOP in a range of 12 to 21 mmHg 3) visual acuity is over 0.7 4) A doctor decides to switch from such drugs to Xalacom combination eye drops
Exclusion criteria
Exclusion criteria: 1) Patients in whom the studied drug is "Contraindication" 2) Patients in whom the studied drug is "Careful Administration" 3) Patients with corneal abnormalities that would hinder the measurement of IOP using Goldmann applanation tonometry 4) Patients whose pupils could dilate so insufficiently that it is impossible to observe optic papillae 5) Patients with a history of a laser treatment 6) Patients with uveititis, an eye injury, an infectious eye disease or an inflammatory eye disease as an accompanying disease 7) Patients with a history of narrow angle that may be closed, or acute angle closure 8) Patients with a retinal disease that might affect the visual field of either or both eyes, as an accompanying disease 9) Patients with a history of an infectious disease within four weeks of participation in this study 10) Patients who had been using any drug that might have a systemic effect that affects intraocular pressure 11) Patients assessed as unsuitable for participation in the study by the investigator and/or subinvestigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intra ocular pressure of 12Weeks after switching from concomitant therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Change rate of intraocular pressure, adherence, safety | — |
Countries
Japan
Outcome results
None listed